Who
Rainer M. Erdtmann
Director and Officer
Company insider
Files Form 4 as: President and COO, Biomea Fusion; Director, Summit Therapeutics; Director, Polarityte; Sr. VP, IR and Admin, Pharmacyclics.
In numbers
- Trades disclosed
- 82
- Buys
- 9
- Sells
- 5
- Bought
- $4.0M
- Sold
- $11.8M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 5 Feb 2009
- Last trade
- 1 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 3 Apr 2026 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —452,512 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —452,512 at $0.00 | filing |
| 31 Dec 2025filed 6 Feb 2026 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —50,600 at $0.00 | filing |
| 31 Dec 2025filed 6 Feb 2026 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —50,600 at $0.00 | filing |
| 31 Dec 2025filed 6 Feb 2026 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 31 Dec 2025filed 6 Feb 2026 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 31 Dec 2025filed 6 Feb 2026 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 31 Dec 2025filed 6 Feb 2026 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 11 Dec 2025filed 15 Dec 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Bought | $43K30,000 at $1.43 | filing |
| 1 Dec 2025filed 2 Dec 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Bought | $11K10,000 at $1.05 | filing |
| 28 Nov 2025filed 2 Dec 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Bought | $44K40,000 at $1.10 | filing |
| 11 Aug 2025filed 13 Aug 2025 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,246,989 at $0.00 | filing |
| 31 Jan 2025filed 13 Aug 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 31 Jan 2025filed 13 Aug 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 31 Jan 2025filed 13 Aug 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 31 Jan 2025filed 13 Aug 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 31 Jan 2025filed 13 Aug 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 31 Jan 2025filed 13 Aug 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 28 Jan 2025filed 13 Aug 2025 | BMEA Biomea FusionBiotechnology | SEC FORM 4 Code G | —40,000 at $0.00 | filing |
| 17 Jan 2024filed 18 Jan 2024 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,700 at $0.00 | filing |
News
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor AgonistBMEA · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Rainer M. Erdtmann; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.